Edition:
India

People: Zogenix Inc (ZGNX.OQ)

ZGNX.OQ on NASDAQ Stock Exchange Global Market

37.39USD
17 May 2019
Change (% chg)

$-0.31 (-0.82%)
Prev Close
$37.70
Open
$37.42
Day's High
$38.03
Day's Low
$37.09
Volume
107,621
Avg. Vol
215,513
52-wk High
$62.75
52-wk Low
$33.56

Farfel, Gail 

Dr. Gail M. Farfel, Ph.D. is an Executive Vice President, Chief Development Officer of Zogenix Inc. From December 2012 to June 2015, she was Chief Clinical and Regulatory Officer of Marinus Pharmaceuticals, where she established and oversaw clinical, medical and regulatory strategies for adult and pediatric seizure disorders, including a pediatric epileptic orphan disease. From May 2008 until December 2012, Dr. Farfel served as President of G. Meredith Consulting LLC, a firm providing strategic consulting and support to biopharmaceutical and software development companies. Dr. Farfel was Vice President, Therapeutic Area and Head for Neuroscience Clinical Development and Medical Affairs at Novartis Pharmaceuticals Corporation from March 2006 through April 2008, in which capacity she oversaw a portfolio of products including Gilenya® for multiple sclerosis, Exelon® and the Exelon® Patch for Alzheimer’s disease and Parkinson’s disease, and the antidepressant, agomelatine. From November 1996 to February 2006, Dr. Farfel held a variety of leadership positions in Clinical Development and Global Medical Affairs at Pfizer, Inc. where she directed programs through all stages of clinical development and regulatory submissions. Dr. Farfel is the author of over 50 scientific articles in the areas of neuropsychopharmacology and drug effects, and holds a Ph.D. in neuropsychopharmacology from the University of Chicago, where she received the Ginsburg Prize for Dissertation Excellence, and a Bachelor’s degree in Biochemistry from the University of Virginia.

Basic Compensation

Total Annual Compensation, USD 554,254
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 362,923
Fiscal Year Total, USD 917,177

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Cam Garner

259,644

Stephen Farr

1,980,630

Michael Smith

1,504,620

Gail Farfel

917,177

Bradley Galer

1,007,910

Ashish Sagrolikar

--
As Of  31 Dec 2017